MEDIA ADVISORY

JOHNSON & JOHNSON PRESS AVAILABILITY: HIV PREVENTION EFFORTS AND UPDATE ON GLOBAL PUBLIC HEALTH AFRICA OPERATIONS

Durban, South Africa – On Tuesday, July 19th at the International AIDS Conference, Johnson & Johnson will host a press availability to discuss HIV prevention tools and methods, including progress from a Phlb/Ila clinical trial based in five countries for its investigational HIV prime boost vaccine regimen, which was initiated based on positive preclinical evidence published in Science last summer, as well as the latest research on a microbicide vaginal ring, a promising prevention technology for women.

The company will also share updates from Johnson & Johnson’s recently launched Global Public Health Africa Operations based in Cape Town, South Africa, including work to build research and development capacity at the University of Cape Town’s Drug Discovery and Development Center; supporting local technology incubators to foster the growth of health venture entrepreneurs and plans to expand coverage for East and West Africa by opening additional satellite offices in Kenya and Ghana.

There will be an opportunity for one-on-one interviews with the speakers after the press availability. If you’d like to schedule an interview with a speaker in advance, please contact Ronan Collins or Katie Buckley by Monday, July 18th. Contact details are included below.

WHO (in alphabetical order):
- Dan Barouch, MD., PhD., Director, Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center; Professor of Medicine, Harvard Medical School
- Seema Kumar, Vice President of Innovation, Global Health and Policy Communication, Johnson & Johnson
- Nelson Michael, M.D., Director of the U.S. Military HIV Research Program, Walter Reed Army Institute of Research
- Zeda Rosenberg, Sc.D., Founding CEO, International Partnership for Microbicides
- Alma Scott, Vice President, Global Operations and Partnerships, Global Public Health, Johnson & Johnson
- Paul Stoffels, M.D., Chief Scientific Officer, Johnson & Johnson

WHEN: Tuesday, July 19, 10:00-10:45 AM

WHERE: Press Conference Room 1 (located outside the Media Centre on the lower level of the Durban International Convention Centre (ICC) by the ICC Arena Entrance)

MEDIA CONTACTS:
Ronan Collins
rcollin5@ITS.JNJ.com
+ 47 488 42500
Katie Buckley
Katie.Buckley@edelman.com
+44 (0)79 7195 6179
About Johnson & Johnson
Caring for the world, one person at a time, inspires and unites the people of Johnson & Johnson. We embrace research and science - bringing innovative ideas, products and services to advance the health and well-being of people. Our approximately 127,100 employees at more than 250 Johnson & Johnson operating companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.

Our Commitment to Global Public Health
For 130 years, Johnson & Johnson has been committed to improving the health of individuals, families and communities around the world, including the most vulnerable populations. Today, our vibrant, entrepreneurial and committed employees bring business acumen and their collaborative spirit to help solve some of the most complex global health problems. By harnessing our collective breadth and scale, and our employees’ passion and purpose, we strive to advance health care and positively impact the lives of all people.

Our Global Public Health Strategy
We have a robust portfolio of innovative products, expertise and experience focused on maternal, newborn and child health, HIV/AIDS and tuberculosis (TB). We use holistic approaches to deliver better health outcomes in addition to quality outputs. And we bring to bear our deep expertise, talent, operational excellence, community engagement and partnerships to build a healthy world free of disease. We work in partnership with governments, donors, non-profits and multilateral institutions to develop and deliver integrated, evidence-based solutions for public health. Learn more at www.jnj.com/global-public-health and follow us @JNJGlobalHealth.